SHESPEAKS Your Power to Influence



Welcome to the SheSpeaks #beBRCAware program. Thank you for joining us to raise awareness of the importance of BRCA testing for those diagnosed with ovarian cancer. We look forward to reading your blog post!

How to Participate in the Program

Important Campaign Links
Hashtag: #beBRCAware
Website: myocjourney.com
Twitter: @beBRCAware
Facebook: https://www.facebook.com/pages/beBRCAware/250939935114040
YouTube: https://www.youtube.com/channel/UCmqqk6o8esolywblpF4-IKQ

Key Messages & Calls to Action for Your #beBRCAware Blog Post

What is a BRCA gene?
BRCA1 and BRCA2 are human genes involved with cell growth, cell division, and cell repair. Although they are most commonly associated with BReast CAncer, approximately 15% of women with ovarian cancer also have BRCA gene mutations.1,2

The Importance of BRCA Testing for Ovarian Cancer
There are a number of misperceptions about BRCA testing, such as the misperception that only those with a family history of breast or ovarian cancer or who are diagnosed at a young age should be tested. But, family history and age are poor predictors of BRCA status in ovarian cancer patients, which is why it is so important for all women with ovarian cancer to be tested.

The Realities of an Ovarian Cancer Diagnosis
For patients with advanced ovarian cancer who have had multiple lines of chemotherapy, the prognosis is poor and treatment options are progressively limited with each additional line of therapy. The American Cancer Society estimates that more than 21,000 new cases of ovarian cancer will be diagnosed in the Unites States in 2015, and that a woman’s risk of developing ovarian cancer is 1 in 73.

How Your Readers Can Help
Encourage your followers to help raise awareness for ovarian cancer during the month of September by having conversations with their friends and family members about ovarian cancer and the importance of BRCA testing, and by sharing one of the images or videos below on their social channels with the hashtag #beBRCAware.

Images for Your Blog Post
Please feel free to use the images below in your blog post, and share them on your social media channels to inspire others to #beBRCAware. Click for full size images.


Videos for Your Blog Post
Please embed at least one of the videos below in your blog post.
 

Submit Your Blog Post
Share your blog link with us by clicking the "submit your blog" button below and adding your blog post URL. Payment will be sent within three business days of completing the assignment and submitting your post.

 

submit your blog

References

1. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807-2816.

2. National Cancer Institute. BRCA1 and BRCA2: Cancer risk and genetic testing. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. Accessed June 2, 2014.

3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2014.

4. Lu KH, Wood ME, Daniels M, et al; American Society of Clinical Oncology. American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol. 2014;32(8):833-840.

5. Pal T, Permuth-Wey J, Betts, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807-2816.

6. Myriad Genetics. http://www.myriadpro.com. Accessed November 18, 2014.

7. Meyer LA, Anderson ME, Lacour RA, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol. 2010;115(5):945-952.

8. Song H, Cicek MS, Dicks E, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Gen. 2014;(April 30):1-7.

9. Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-2663.